The goal of the research projects in this program is to understand the oncogenomic changes in myeloma central to disease pathogenesis which impact clinical outcome using data from two large clinical trials To support this effort, the Bioinformatics and Biostatistics Core E will provide 1) support and direction on the formatting, quality control and annotation procedures of clinical and research data as well as the process of transferring the research data a data warehouse for integrative analysis, 2) bioinformatics support for primary and integrative analysis of the high-throughput data on genetic lesions, gene expression and transcriptome modification by differential miRNA expression and alternative splicing and 3) biostatistics support in terms of design and analysis for all projects. Core members will work closely with project members as well as Cores A and B with regard to quality control, specimen tracking and data warehouse procedures as well as Cores C and D which will perform microarray based gene and miRNA expression profiling, and SNP genotyping and next generation sequencing for identifying genomic and transcriptomic changes. Bioinformatics and biostatistics support and analysis is not only required for individual projects, but it is crucial for the integrative analysis from data across the projects and thus overall success of the program.

Public Health Relevance

This core will help analyze both clinical data to identify role of transplantation in myeloma in the era of novel agents and identify correlates of clinical out come. The bioinformatic support will unravel genomic changes to better understand disease biology, features predictive of progression to myeloma and define those changes that will predict outcome and will form the basis for development of novel therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA155258-04
Application #
8733622
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
4
Fiscal Year
2014
Total Cost
$129,370
Indirect Cost
$33,348
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Miannay, Bertrand; Minvielle, Stéphane; Magrangeas, Florence et al. (2018) Constraints on signaling network logic reveal functional subgraphs on Multiple Myeloma OMIC data. BMC Syst Biol 12:32
Samur, Mehmet Kemal; Minvielle, Stephane; Gulla, Annamaria et al. (2018) Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia 32:2626-2635
Singh, Irtisha; Lee, Shih-Han; Sperling, Adam S et al. (2018) Widespread intronic polyadenylation diversifies immune cell transcriptomes. Nat Commun 9:1716
Xu, Yan; Deng, Shuhui; Mao, Xuehan et al. (2018) Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18:422-430
Bolli, Niccolo; Biancon, Giulia; Moarii, Matahi et al. (2018) Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 32:2604-2616
Botta, C; Cucè, M; Pitari, M R et al. (2018) MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia 32:1003-1015
Zeid, Rhamy; Lawlor, Matthew A; Poon, Evon et al. (2018) Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat Genet 50:515-523
Maura, F; Petljak, M; Lionetti, M et al. (2018) Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia 32:1044-1048
Bae, J; Hideshima, T; Zhang, G L et al. (2018) Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia 32:752-764
O'Donnell, Elizabeth K; Laubach, Jacob P; Yee, Andrew J et al. (2018) A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 182:222-230

Showing the most recent 10 out of 218 publications